

FOR IMMEDIATE RELEASE**HC Surgical Specialists Posts Record S\$5 million Profit to Shareholders
for HY2021, More than Double (2.3x) of HY2020****HY2021 RESULTS HIGHLIGHTS**

- Revenue increased 12.4% to S\$10.98 million post-circuit breaker in HY2021
- HY2021 Profit to Shareholders increased 130.8% year-on-year to S\$5 million
- Declared highest interim dividend of S\$0.017 per ordinary share

Singapore, 13 January 2021 – Catalyst-listed HC Surgical Specialists Limited (SGX:1B1) (“HCSS”, or collectively with its subsidiaries, the “Group”) announced its financial results for the half year ended 30 November 2020 (“HY2021”) today.

Financial Overview (Group)

S\$' million	HY2021	HY2020	Change %
Revenue	10.98	9.77	12.4%
Gross Profit*	9.56	8.71	9.7%
Profit Attributable to Owners of the Company	5.00	2.17	130.8%
Earnings Per Share (S\$ cents)	3.32	1.45	129.0%

*Gross Profit is calculated as Revenue - change in inventories – inventories, consumables and surgery expenses.

The Group’s HY2021 revenue increased by 12.4% to S\$10.98 million due to the pent-up demand for its services post-circuit breaker since 2 June 2020.

The increase in other income of approximately S\$0.24 million was mainly due to higher government grants (including the Jobs Support Scheme) of approximately S\$0.27 million and higher dividend income from investment in financial assets at fair value through profit or loss (“FVTPL”) of approximately S\$0.04 million, which was partially offset by a decrease in interest income.

Fair value gain on financial assets at FVTPL of S\$1.54 million primarily arose due to (i) the increase in share price of Medinex Limited (“Medinex”) in which the Company holds a direct interest of 22.92% and a deemed interest of 9.50% of the total issued share capital; and (ii) the increase in fair value of investment in Singapore Paincare Holdings Limited subsequent to its listing on the Catalist Board of the Singapore Exchange Securities Trading Limited on 30 July 2020 based on the quoted market share price. In HY2020, the fair value loss on financial assets at FVTPL of S\$0.60 million was due to the decrease in share price of Medinex.

As a result of the aforementioned, the Group recorded a profit attributable to owners of the Company of S\$5.0 million in HY2021.

Dividend

The Directors are recommending an interim dividend of 1.7 Singapore cents payable on 2 February 2021.

Annotating on the Group’s HY2021 results, Chief Executive Officer of HCSS, Dr. Heah Sieu Min said, ***“We are happy that our hard work has shown good results. The HY2021 performance is built upon the cohesiveness and relentless spirit of all the staff amidst this COVID-19 pandemic situation, on top of patients’ belief and trust in our quality care for them. I am confident that as Singapore and the world emerge from the pandemic, HCSS will continue in our pursuit to bringing “quality healthcare to the doorsteps” of many more in our community. As part of the Group’s corporate social responsibility program, we held our inaugural Charity Event in July 2020, in line with the COVID-19 guidelines issued by the Ministry of Health, and donated a sum of S\$73,414 to the President’s Challenge and The Courage Fund.*”**

As a reward to our shareholders who have supported us during this difficult period, we have raised our interim dividend by 30% to S\$0.017 per ordinary share, which is in line with our improved core operational performance.”

Moving Forward

The Group will begin operations at a new endoscopy centre in Toa Payoh in the second half of its financial year, having obtained its medical licence from the Ministry of Health (the “**MOH**”) in December 2020.

Although the COVID-19 pandemic has resulted in a drop in the number of foreign patients, the Group has not suffered much impact as we are able to rely on the local population demands for our services. The strategy of developing a wide network of centres located within the heartlands of Singapore enables the Group to adapt to the “new norm” and at the same time maintaining safe distancing measures in accordance with MOH guidelines.

Dr. Heah Sieu Min added, ***“The Group has always placed great emphasis on providing quality services for our patients. Our centres are MediSave accredited, enabling convenient payments including MediShield plan claims. Evening clinics are available for patients to visit after office hours. All 12 endoscopy centres are accessible via public transport. Our team of dedicated doctors and staff are committed to provide the best medical care for our patients.***

We see our collaborations with insurance partners as an opportunity to serve a greater proportion of the community. It is in line with our motto to bringing ‘healthcare to your doorstep’.”



Incorporated in the Republic of Singapore
Registration No. 201533429G

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (“HCSS”) was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. HCSS and its subsidiaries is a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies and general surgery services with a focus on colorectal procedures across a network of 18 clinics located throughout Singapore. For more information, please visit HCSS’ website at www.hcsurgicalspecialists.com.

Issued By : HC Surgical Specialists Limited

Investor Relations Contact : contact@hcsurgicalspecialists.com

This press release has been prepared by the Company and reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “Sponsor”), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made, or reports contained in this press release.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.